For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Cohort 1 (Ocular) | HMIOL implantation with no optic exchange Events reported in this group occurred in the study eye from time of consent to study exit (up to 15 months) | 0 | None | 2 | 51 | 2 | 51 | View |
| Cohort 2 Pre-exchange (Ocular) | HMIOL implantation pre-optic exchange Events reported in this group occurred in the study eye from time of consent to time of optic exchange (up to 6 months) | 0 | None | 2 | 65 | 1 | 65 | View |
| Cohort 2 Post-exchange (Ocular) | HMIOL implantation post-optic exchange Events reported in this group occurred in the study eye from time of optic exchange to time of study exit (up to 12 months) | 0 | None | 0 | 65 | 6 | 65 | View |
| Fellow Eye (Ocular) | IOL per standard of care Events reported in this group occurred in the fellow eye from time of consent to study exit (up to 15 months if study eye was enrolled in Cohort 1, up to 18 months if study eye was enrolled in Cohort 2) | 0 | None | 2 | 114 | 5 | 114 | View |
| Systemic (Non-ocular) | Events reported in this group occurred from time of consent to study exit (up to 15 months if subject was enrolled in Cohort 1, up to 18 months if subject was enrolled in Cohort 2) | 0 | None | 4 | 114 | 0 | 114 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Neovascular age-related macular degeneration | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Acute myocardial infarction | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Endophthalmitis | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Posterior Capsule Rupture | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Breast cancer stage II | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | None | View |
| Cerebrovascular accident | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Parkinsonism | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Eye operation | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Intraocular lens implant | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Surgery | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Dry eye | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |